Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Chinese Patent Office
Medtronic
Merck
Chubb

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,580,520

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,580,520
Title:YKL-40 as a marker for gastrointestinal cancers
Abstract: The present invention relates to gastrointestinal cancers and methods for selecting a treatment for said gastrointestinal cancer in a subject. The present invention further relates to a methods of diagnosing the presence of and/or classifying the severity of a gastrointestinal cancer; together with methods for determining the effect of a therapy administered and/or the prognosis for a subject suffering from a gastrointestinal cancer, before, during or after administering the treatment. For all the methods applies that a determined level of YKL-40 above one or more reference levels indicates the treatment, the severity of the disease, the effect of the treatment and/or the prognosis of the subject. The reference level is typically a level obtained from healthy individuals or a level previously obtained from the same subject. The subject may suffer from any one or more gastrointestinal cancers, such as upper gastrointestinal cancers, and metastatic colorectal cancer. The present invention further relates to a kit and a device that may be used in the method of the present invention.
Inventor(s): Johansen; Julia Sidenius (Frederiksberg, DK), Schultz; Nicolai Aagaard (Frederiksberg, DK), Jensen; Benny Vittrup (Roskilde, DK), Bojesen; Stig (Kobenhavn O, DK), Nordestgaard; Borge Gronne (Genrofte, DK), Nielsen; Hans Jorgen (Kongens Lyngby, DK), Christensen; Ib Jarle (Hillerod, DK)
Assignee: Herlev Hospital (Herlev, DK) Rigshospitalet (Kobenhavn O, DK) Hvidovre Hospital (Hvidovre, DK)
Application Number:13/063,402
Patent Claims:see list of patent claims

Details for Patent 8,580,520

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Herlev Hospital (Herlev, DK) Rigshospitalet (Kobenhavn O, DK) Hvidovre Hospital (Hvidovre, DK) 2028-09-15 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27 ➤ Sign Up Herlev Hospital (Herlev, DK) Rigshospitalet (Kobenhavn O, DK) Hvidovre Hospital (Hvidovre, DK) 2028-09-15 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ➤ Sign Up Herlev Hospital (Herlev, DK) Rigshospitalet (Kobenhavn O, DK) Hvidovre Hospital (Hvidovre, DK) 2028-09-15 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ➤ Sign Up Herlev Hospital (Herlev, DK) Rigshospitalet (Kobenhavn O, DK) Hvidovre Hospital (Hvidovre, DK) 2028-09-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fuji
Healthtrust
Argus Health
QuintilesIMS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.